ole‐3,2′‐[1,2,4]triazolo[1,5‐c]quinazolin]‐2‐one (20, Ki human A3AR 6.94 nm). In addition, multitarget antagonists were obtained, such as the dual A1/A3 antagonist 2,5‐diphenyl[1,2,4]triazolo[1,5‐c]quinazoline (13 b, Ki human A1AR 51.6 nm, human A3AR 11.1 nm), and the balanced pan‐AR antagonists 5‐(2‐thienyl)[1,2,4]triazolo[1,5‐c]quinazolin‐2‐amine (11 c, Ki human A1AR 131 nm, A2AAR 32.7 nm, A2BAR
2‐
氨基[1,2,4]三唑并[1,5 ‐c ]
喹唑啉被确定为有效的
腺苷受体(AR)拮抗剂。设计了合成策略以获取包括新的多
杂环化合物在内的广泛衍
生物。发现了有效和选择性的A 3 AR拮抗剂,包括3,5-二苯基[1,2,4]三唑并[4,3- c ]
喹唑啉(17,K i人A 3 AR 1.16 n m)和5'-苯基-1,2-二氢-3' ħ -螺[
吲哚-3,2' - [1,2,4]三唑并[1,5- c ^ ]
喹唑啉] -2-酮(20,ķ我人阿3 AR 6.94牛顿米)。此外,还获得了多靶点拮抗剂,例如双重A 1 / A 3拮抗剂2,5-二苯基[1,2,4]三唑并[1,5- c ]
喹唑啉(13 b,K i人A 1 AR 51.6 n m,人类A 3 AR 11.1 n m)和平衡的pan-AR拮抗剂5-(2-
噻吩基)[1,2,4]三唑[1,5 - c ]
喹唑啉-2-胺(11 c,K i人A 1 AR